Lv34
240 积分 2026-02-26 加入
EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling
59分钟前
已完结
Resistance Mechanisms of Alectinib in ALK-Positive Non-Small Cell Lung Cancer and Therapeutic Strategies
2小时前
已完结
An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer
2小时前
已完结
Arrhythmogenic effects of tyrosine kinase inhibitors: a narrative review
22小时前
已关闭
Targeted therapies in non–small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management
22小时前
已关闭
MA10.03 Efficacy and Safety of Cadonilimab Plus Pulocimab in NSCLC Patients Who Progressed Following Prior Immunotherapy: A Phase 1b/2 Study
2天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
2天前
已完结
Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial
3天前
已完结
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
3天前
已完结
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
6天前
已完结
皖公网安备34019202002308
